Although, direct sequencing is the gold standard for KRAS mutation detection in routine diagnostics, it remains laborious, time consuming and not very sensitive.
Introduction
Since the introduction of targeted therapy against the epidermal growth factor receptor (EGFR) for the treatment of metastatic colorectal cancer, mutation detection in downstream effector molecules like KRAS has become clearly more important in clinical practice. It has been well reported in literature that patients harbouring mutations in these molecules will not benefit from anti-EGFR treatment 1, 2 . Several mutations have been described in the KRAS gene, impairing response to anti-EGFR therapy. These mutations occur most frequently (97%) in codons 12 and 13 of exon 2 (the first coding exon); less common (3%) are the mutations in codons 59 and 61 in exon 3 3 . The clinical value of these latter mutations is still unknown. KRAS mutations occur early in colorectal carcinogenesis and are present in 30 up to 40% of colorectal carcinoma cases, independently of disease stage 4 .
Recently, the American Society of Clinical Oncology (ASCO) has issued the recommendation to test for KRAS mutations in all patients with metastatic colorectal cancer before treatment with cetuximab 5 . Moreover, in Europe KRAS mutation analysis in stage II and III colon cancer has been recommended by an expert panel 6 . Thus, KRAS mutation detection plays an important role in colon cancer therapy decision making and could very well become one of the most frequently performed tests in diagnostic pathology laboratories in the future.
Accurate mutation detection depends on several factors, including available tissue, DNA quality, DNA input and tumor cell percentage. All are important issues in limiting assay performance and sensitivity. The majority of assays in clinical practice are performed on formalin fixed paraffin embedded (FFPE) resection material. DNA from FFPE material is often of poor quality, impairing the performance of existing assays.
Furthermore, DNA input can be a problem when little tissue is available as in needle biopsies. In addition, small numbers of tumor cells in a background of stromal cells can sometimes be challenging for accurate mutation detection as in the case of radio-and/ or chemotherapy pre-treated tumor specimens. When choosing an assay for routine diagnostics, additional factors such as workload, 
KRAS PCR and dideoxy sequencing
PCR for the amplification of codons 12 and 13 in exon 2 was performed using the primers described elsewhere 12 . The expected product length was 170 bp.
Subsequently, 206 PCR products were purified using the QIAquick gel extraction kit (Qiagen, Venlo, the Netherlands) following manufacturer's instructions whereas 90 PCR products were purified by the enzymatic reaction with ExoSapIT (USB Co, Staufen, Germany). The change in purification method was due to the less laborious character of enzymatic purification, not affecting quality of sequence results. Purified products were then sequenced using the same primers as for the amplification and Big Dye Terminator v1.1 cycle sequence kit (Applied Biosystems, Nieuwerkerk aan de IJssel, the Netherlands). Sequencing products were separated in the ABI 3100 and analyzed using the Sequencing Analysis 5.3.1 software (Applied Biosystems, Nieuwerkerk aan de IJssel, the Netherlands). Based on the fact that in our laboratory we have not found any discrepancy between KRAS mutation detection in wild type KRAS cases by sequencing with the forward or the reverse primer and to decrease workload, reactions were initially performed with the reverse primer. When a mutation was found, this was confirmed in a newly generated PCR product using the forward primer.
KRAS SNaPshot
PCR was performed using the same primer pair as for dideoxy sequencing 12 .
Subsequently, products were purified with ExoSapIT (USB, Staufen, Germany). Next the single nucleotide primer extension reaction was performed as previously described The primers have a certain length and end one nucleotide before the mutation. Subsequently, one fluorochrome labelled dideoxynucleotide is added. Using capillary electrophoresis products are separated according to size. Depending on the nucleotide build in after primer extension either one or two of the fluorochromes will be detected depending on the genotype.
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KRAS StripAssay™
The KRAS StripAssay™ as recently described by Ausch et al 11 was performed according to manufacturer's instructions (Vienna Labs, Vienna, Austria). Briefly summarized, a PCR enriched for mutant KRAS alleles is performed. This PCR is based on wild type sequence clamping with a specific PNA oligonucleotide, allowing preferred amplification of the mutant sequence 13; 14 . Subsequently, PCR products are hybridized to a nitrocellulose strip containing specific probes for the different mutations (figure 2).
After hybridization, the test strip is washed, blocked and color is developed 11 . 
Results
Technical validation: Sensitivity, specificity and performance. figure   3 and 4). Finally, the StripAssay™ appeared to be the most sensitive technique with a mutation detection limit of 1% tumor cells (table 1 and figure 4).
To investigate possible false positivity of the StripAssay™, additional samples, known to be wild type KRAS by direct sequencing and SNaPshot were tested by the StripAssay™ and sequencing of the clamped PCR product. Two conflicting results were found. Mutations were seen only by sequencing but products did not hybridize to the nitrocellulose strip. The mutations found were c.34G>A; p.Gly12Ser and c.39C>A with no aminoacid substitution. These samples were tested again and no mutants were found, neither with the StripAssay™ nor by direct sequencing.
Specificity
Previously tested samples with known mutations were used to check specificity of the different techniques. Although, c.37G>C; p.Gly13Arg, c.37G>A; p.Gly13Ser and c.38G>C; p.Gly13Ala were not seen in our samples, we believe that they are detectable with direct sequencing and SNaPshot just like the other nine mutations in codons 12 and 13 which were detected by both sequencing and SNaPshot. Of the mutations present in our series, the StripAssay™ failed to detect the c.38G>T; p.Gly13Val mutation because it is not present on the strip (Figure 2 ). 
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Clinical validation
KRAS mutations were found in 107 of the 296 colon cancer samples tested, 36% of the study group. Table 3 shows the frequencies of the different mutations found in these samples. On average, mutation frequencies were in agreement with frequencies published in the COSMIC database (http://www.sanger.ac.uk/genetics/CGP/cosmic/ viewed June 30 th , 2010). These results were identical with direct sequencing and with single nucleotide primer extension. The c.38G>T; p.Gly13Val mutation which is not available in the StripAssay™ was found in one sample from the 296 in this cohort. 
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Discussion
The recent advices from the ASCO and a European expert panel to perform KRAS mutation detection prior to therapy with cetuximab in metastatic colorectal cancer 5 and in stage II and III colon cancer 6 , respectively, has made the need for a sensitive, flexible, fast and easy to implement in daily practice assay urgent. Therefore, we compared three currently available techniques for implementation in routine diagnostics. The gold standard direct sequencing was compared to "in house" developed SNaPshot and partly to the commercially available StripAssay™.
Several parameters were accounted for including sensitivity, specificity, workload, time to results, hands-on time, flexibility and costs. However, the choice of a technique also depends on other variables such as equipment, expertise and personnel available in a molecular diagnostics laboratory.
In this study, SNaPshot showed to be a very sensitive technique which performed well with paraffin embedded tissues. Without any mutant DNA enrichment strategy before the KRAS specific PCR, we obtained reproducible and robust results in the entire cohort of patients tested. All mutations previously obtained with direct sequencing were confirmed with the SNaPShot technique and frequencies agreed with the COSMIC database (table 3) . The fully consistent results between SNaPshot and direct sequencing can be explained by the selection of samples. All samples must contain more than 30% tumor cells, which in turn is higher than the detection threshold for both techniques 10 and 20% respectively. Moreover, both techniques compared are performed using different PCR products, but the same DNA extracted from clinical specimens. We know that DNA extraction is a crucial factor for test reproducibility and subsequent possible differences in sensitivity. Workflow is similar to direct sequencing, hands-on time post DNA extraction is approximately two hours whereas time to results after DNA isolation is approximately one and a half working days. In our opinion, the SNaPshot assay has two main advantages when compared to direct sequencing. First, SNaPshot was more sensitive than dideoxy sequencing being able to detect mutations in samples containing 10% tumor cells in a background of wild type cells. Second, this technique is very flexible. It is easily extendible to other KRAS mutations and to mutations in other genes like for instance the BRAF V600E mutation. This characteristic can be important in the future. With the introduction of more targeted therapies it seems likely that gene mutation detection is going to be a cornerstone in molecular diagnostics. This flexibility
5
can save diagnostic time and material input, besides reducing costs 15 . However, primer design can be complicated and the use of multiplex reactions could affect sensitivity and therefore this issue should be addressed before implementing it in daily practice.
In our hands, the most sensitive assay was the StripAssay™ based on mutant enriched PCR followed by reverse hybridization. The mutant enriched PCR is based on the clamping of the wild type sequence by PNA nucleotides therefore, only mutant DNA template is amplified. With this technique mutations were detected in samples containing as little as 1% tumor cells in a wild type background. These results are in agreement with previous reports using cell lines 11 where the same sensitivity was found for mutation detection.
Although the hybridization to a specific probe after PCR amplification minimizes the risk of false positive results, one drawback of PNA PCR clamping can be false positivity due to Taq polymerase errors under the clamp depending on the amount of DNA template 16; 17 . Thus, one should be aware of the fact that false positivity is a real concern when using techniques based on PNA PCR clamping. However, in our case, it is difficult to assess whether the false positivity was introduced during the PCR or during sequencing. The fact that clamped PCR products did no hybridize to the StripAssay™ but were found after sequencing, indicates that at least in one sample the error occurred during sequencing. Nevertheless, to minimize the risk of false positivity introduced by
Taq polymerase errors, assays should be performed in duplicate and manufacturer's instructions concerning DNA input, should be strictly followed. The latter, might be a difficult issue when using FFPE, since measurement of DNA amount is often unreliable. . It is rapid, sensitive and accurate 19 . By screening all samples with HRM, only aberrant samples need to be further analyzed to determine the underlying mutation, thereby decreasing sequencing workload. However, costs might increase, when no dedicated technology for HRM is present and must be additionally bought. Pyrosequencing is a sensitive, rapid and less laborious technique that can be a good alternative to direct sequencing. An advantage of pyrosequencing is that it is a quantitative assay which does not need PCR product manipulation diminishing contamination risk 8 . Finally, real time allelic discrimination could also be a good alternative for direct sequencing because of the rapidity and high sensitivity of the technique; however, the difficulty of multiplexing and the similarity between the 5 9 probes lead to higher DNA input and a high risk of decreased specificity due to cross reactivity of the different probes 10 .
When considering all aspects, we conclude that for colon cancer diagnostics, in which, sensitivity is generally not an issue and when capillary electrophoresis facilities are already available, SNaPshot can be as valuable as direct sequencing. Workflow, time to results, hands-on time and costs do not vary much between both techniques. However, the multiplex possibilities of the SNaPshot can reduce DNA input, costs and workload.
Thus SNaPshot is a good alternative for direct sequencing for KRAS mutation detection in colon cancer patients in daily diagnostic practice. However, when sensitivity is an important issue such as in the case of lung cytology samples, or for small laboratories without dedicated equipment, highly sensitive techniques like the StripAssay™ should be considered due to its high sensitivity, rapidity and ease to perform. Nevertheless, one should be aware of the false positivity risks of such a technique and perform assays in duplicate to avoid false positives.
